Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-track ...

Parabilis Medicines CEO Mathai Mammen, M.D., Ph.D., told Fierce the industry had been in “retreat mode for some time” before its latest rebound. (mesh cube/iStock/Getty Images Plus) Elon Musk's SpaceX ...

The University of Sheffield, UK is inviting applications for its BSc Biochemistry course starting in September 2026.

The Food and Drug Administration is rudderless. Its commissioner, Marty Makary, is gone. Much of the agency’s senior leadership has been purged, and the scientific ranks have been hollowed out. For ...

Biotech investors are finally getting something they haven't seen in years: a friendlier macro environment. Interest rates appear to be stabilizing, FDA activity is picking up again, and large ...

Krystal Biotech leverages its HSV-1 gene delivery platform, with VYJUVEK generating strong cash flow and 95% gross margins since FDA approval. KRYS is rated Buy, justified by a robust ...

Odyssey Therapeutics Inc., a clinical stage biotechnology firm focused on autoimmune and inflammatory diseases, is seeking to raise $238.3 million in an initial public offering. The Boston-based ...

Artificial intelligence has dominated investor attention for two years, but biotech revenue lines are also bending sharply higher. A small group of biotechs is building real commercial businesses ...

The biotech IPO window looks like it’s reopening. This past week closed with three biotech companies joining the public markets, a flurry of activity that helped make April the biggest month for ...

Studies utilizing Gemelli’s proprietary diagnostic technologies demonstrate key clinical applications, advancements in IBS and SIBO diagnostics, and treatment support. These findings will be presented ...

Biopharma companies appear to be more willing to go public after a long drought. Just this week, GLP-1 developer Kailera Therapeutics and proteomics company Alamar Biosciences launched IPO roadshows ...